Skip to main content
March 28, 2025

As of March 26, 2025, the European Health Data Space (EHDS) Regulation has officially entered into force. This is the first EU-wide data space dedicated to a specific sector, launched under the European Data Strategy. It aims to revolutionize how health data is accessed, shared, and reused across the EU, with full implementation planned by 2034.

⚖️ A Dual-Purpose Framework

The EHDS pursues two core objectives:

Primary use: to improve patient care by ensuring individuals and healthcare professionals have secure and seamless access to electronic health data across borders.

Secondary use: to enable researchers, public authorities, and industry to access anonymized or pseudonymized health data for research, innovation, public health, policymaking, and regulatory purposes — under strict conditions.

📆 Phased Implementation

By 2027: Each Member State must establish a Digital Health Authority to oversee national implementation.

By 2029: Primary use rules will apply across the EU, allowing cross-border access to key categories of health data (e.g., EHRs, ePrescriptions).

By 2031: Secondary use of health data will become fully operational.

By 2034: Third-country entities may request access if they meet EU reciprocity and adequacy conditions.

What It Means for Practitioners

EHDS introduces both opportunities and challenges for the healthcare and Life Sciences sectors:

Compliance with the EHDS must align with the GDPR, NIS2 Directive, Data Act, and the Data Governance Act.

Individuals can access, correct, or restrict certain uses of their health data.

Systems must meet EU-wide interoperability standards.

For instance, Germany mandates that health and social data be processed within its territory or in an EU-adequate country.

A Game-Changer for Research & Innovation

For CROs and biopharma companies, the EHDS represents a major shift in the way clinical research and innovation are conducted across Europe. It provides access to large-scale, high-quality health datasets that can significantly enhance clinical trial design, epidemiological research, and real-world evidence generation. By offering a structured and interoperable data environment, the EHDS accelerates the development of AI-driven diagnostics and digital health applications, unlocking new frontiers in personalized medicine. Additionally, it simplifies the execution of multinational trials by reducing administrative burdens and facilitating patient recruitment across EU Member States—ultimately enabling faster, more efficient, and more inclusive research.

A Transparent and Secure Ecosystem

The EHDS is built on a transparent and secure ecosystem, designed to foster trust among all stakeholders. Access to health data will be managed by Health Data Access Bodies (HDABs), which will evaluate requests and grant approvals within three months—a substantial improvement over current lengthy and fragmented procedures. Once approved, data can only be used within highly secure, EU-regulated environments; raw data cannot be downloaded or extracted outside these frameworks. Furthermore, organizations using EHDS data will be required to publish the results of their research within 18 months, ensuring that insights generated from public data ultimately serve the public good.

Looking Ahead

The European Health Data Space (EHDS) marks a transformative shift in how Europe handles health data — creating new momentum for data-driven research, digital innovation, and improved patient care. For healthcare professionals, CROs, and the biopharma industry, now is the time to understand the implications, anticipate compliance challenges, and explore the strategic opportunities that lie ahead.

Whether you are in clinical development, regulatory affairs, digital health, or data governance, the EHDS will shape the future of your work. Let’s be ready.

👉🏻 Any question? Contact our experts 📧 [email protected]

Victoria Derumier

DPO & BE Entity Director